b'BLEED: 8.375"wTRIM: 7.875"w SAFETY: 6.875"w 1L aRCC +CODE_CABOMETYX_RCC_3PG_Efficacy In Balance JournalAd_7.875" x 10.5_A-Size_Page SAFETY: 9.5"hTRIM: 10.5"hBLEED: 11.25"hA BALANCE OF DATA*1L aRCC treatment that offers a balance of data:SUPERIOR OS SAFETY & QUALITYsuperior OS, safety and tolerability,vs sunitinib TOLERABILITY OF LIFEand patient-reported quality of life 1-4**Superior OS vs sunitinib in patients with previously untreated aRCC. Primary analysis OS results: 40% reduction in risk of death with CABOMETYX + OPDIVO vs sunitinib (HR=0.60; 98.89% CI: 0.40-0.89; P=0.001); median OS was not reached in either arm. The primary endpoint was PFS, and secondary endpoints included OS, ORR, and safety. Quality of life was evaluated as an exploratory endpoint using the FKSI-19 scale, and the clinical signi cance is unknown 1 . ,21L= rst-line; aRCC=advanced renal cell carcinoma; CI=con dence interval; FKSI-19=Functional Assessment of Cancer Therapy-Kidney Symptom Index 19; HR=hazard ratio; ORR=objective response rate; OS=overall survival; PFS=progression-free survival.INDICATIONSCABOMETYX (cabozantinib), in combination with nivolumab, is indicated for therst-line treatment of patients with advanced renal cell carcinoma (RCC).CABOMETYX is indicated for the treatment of patients with advanced RCC.IMPORTANT SAFETY INFORMATIONWARNINGS AND PRECAUTIONSHemorrhage: Severe and fatal hemorrhages occurred with CABOMETYX. The incidence of Grade 3 to 5 hemorrhagic events was 5% in CABOMETYX patients in RCC, HCC, and DTC studies. Discontinue CABOMETYX for Grade 3 or 4 hemorrhage and prior to surgery as recommended. Do not administer CABOMETYX to patients who have a recent history of hemorrhage, including hemoptysis, hematemesis, or melena. Perforations and Fistulas: Fistulas, including fatal cases, occurred in 1% of CABOMETYX patients. Gastrointestinal (GI) perforations, including fatal cases, occurred in 1% of CABOMETYX patients. Monitor patients for signs and symptoms ofstulas and perforations, including abscess and sepsis. Discontinue CABOMETYX in patients who experience a Grade 4stula or a GI perforation. Thrombotic Events: CABOMETYX increased the risk of thrombotic events. Venous thromboembolism occurred in 7% (including 4% pulmonary embolism) and arterial thromboembolism in 2% of CABOMETYX patients. Fatal thrombotic events occurred in CABOMETYX patients. Discontinue CABOMETYX in patients who develop an acute myocardial infarction or serious arterial or venous thromboembolic events that require medical intervention.Hypertension and Hypertensive Crisis: CABOMETYX can cause hypertension, including hypertensive crisis. Hypertension was reported in 37% (16% Grade 3 and 1% Grade 4) of CABOMETYX patients. Do not initiate CABOMETYX in patients with uncontrolled hypertension. Monitor blood pressure regularly during CABOMETYX treatment. Withhold CABOMETYX for hypertension that is not adequately controlled with medical management; when controlled, resume at a reduced dose. Permanently discontinue CABOMETYX for severe hypertension that cannot be controlled with anti-hypertensive therapy or for hypertensive crisis.Please see additional Important Safety Information throughout and Brief Summary of the Prescribing Information for CABOMETYX on following pages.'